Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Colorectal Neoplasms | 88 | 2024 | 6919 | 6.820 |
Why?
|
Colonic Neoplasms | 17 | 2023 | 2527 | 2.470 |
Why?
|
Vitamin D | 23 | 2023 | 3301 | 1.990 |
Why?
|
Pancreatic Neoplasms | 37 | 2023 | 5366 | 1.900 |
Why?
|
Cholecalciferol | 7 | 2020 | 552 | 1.860 |
Why?
|
Vitamins | 11 | 2023 | 1634 | 1.670 |
Why?
|
Calcifediol | 3 | 2019 | 160 | 1.470 |
Why?
|
Carcinoma, Pancreatic Ductal | 13 | 2023 | 1726 | 1.230 |
Why?
|
Adenocarcinoma | 18 | 2023 | 6341 | 1.220 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 24 | 2023 | 11733 | 1.180 |
Why?
|
Coffee | 2 | 2021 | 593 | 1.060 |
Why?
|
Vitamin D-Binding Protein | 3 | 2023 | 130 | 0.980 |
Why?
|
Dietary Supplements | 10 | 2021 | 3410 | 0.850 |
Why?
|
Vitamin D Deficiency | 7 | 2021 | 1388 | 0.840 |
Why?
|
Cyclooxygenase 2 Inhibitors | 2 | 2015 | 321 | 0.830 |
Why?
|
Feeding Behavior | 6 | 2021 | 3183 | 0.800 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 3 | 2023 | 380 | 0.770 |
Why?
|
Digestive System Neoplasms | 1 | 2021 | 83 | 0.750 |
Why?
|
Microsatellite Instability | 9 | 2023 | 716 | 0.750 |
Why?
|
Prospective Studies | 59 | 2024 | 54435 | 0.700 |
Why?
|
Proportional Hazards Models | 29 | 2021 | 12474 | 0.680 |
Why?
|
Diet | 10 | 2024 | 8048 | 0.680 |
Why?
|
Neoplasm Recurrence, Local | 11 | 2020 | 9278 | 0.660 |
Why?
|
Hyperinsulinism | 2 | 2020 | 400 | 0.650 |
Why?
|
Histamine H2 Antagonists | 1 | 2020 | 166 | 0.640 |
Why?
|
Janus Kinase 1 | 1 | 2018 | 107 | 0.610 |
Why?
|
Middle Aged | 104 | 2024 | 220853 | 0.600 |
Why?
|
Fluorouracil | 7 | 2022 | 1642 | 0.570 |
Why?
|
Picornaviridae Infections | 1 | 2018 | 95 | 0.560 |
Why?
|
Insulin | 6 | 2019 | 6588 | 0.560 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 3 | 2017 | 2270 | 0.560 |
Why?
|
Rhinovirus | 1 | 2018 | 203 | 0.550 |
Why?
|
Leukemia | 2 | 2022 | 1518 | 0.540 |
Why?
|
Humans | 176 | 2024 | 761208 | 0.540 |
Why?
|
Rectal Neoplasms | 2 | 2022 | 1156 | 0.530 |
Why?
|
Receptor, erbB-2 | 5 | 2024 | 2553 | 0.530 |
Why?
|
Early Detection of Cancer | 6 | 2023 | 3198 | 0.520 |
Why?
|
Flavivirus Infections | 1 | 2015 | 14 | 0.520 |
Why?
|
Chemotherapy, Adjuvant | 10 | 2018 | 3512 | 0.520 |
Why?
|
Aged | 83 | 2024 | 169288 | 0.520 |
Why?
|
Respiratory Tract Diseases | 1 | 2021 | 748 | 0.510 |
Why?
|
Aspirin | 4 | 2021 | 3129 | 0.510 |
Why?
|
Proton Pump Inhibitors | 1 | 2020 | 534 | 0.490 |
Why?
|
Breast Feeding | 1 | 2023 | 1356 | 0.490 |
Why?
|
Janus Kinase 2 | 1 | 2018 | 559 | 0.490 |
Why?
|
Risk Factors | 51 | 2024 | 74239 | 0.460 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 2016 | 344 | 0.450 |
Why?
|
Drug Users | 1 | 2015 | 134 | 0.450 |
Why?
|
Interleukin-6 | 2 | 2023 | 3210 | 0.440 |
Why?
|
Female | 113 | 2024 | 392544 | 0.440 |
Why?
|
Neoplasm Staging | 18 | 2021 | 11119 | 0.420 |
Why?
|
Adult | 73 | 2024 | 221119 | 0.420 |
Why?
|
Male | 100 | 2024 | 360693 | 0.410 |
Why?
|
Camptothecin | 6 | 2022 | 591 | 0.410 |
Why?
|
Disease-Free Survival | 12 | 2023 | 6819 | 0.410 |
Why?
|
Stomach Neoplasms | 4 | 2023 | 1457 | 0.400 |
Why?
|
ras Proteins | 4 | 2013 | 1055 | 0.400 |
Why?
|
Calcium, Dietary | 3 | 2019 | 529 | 0.370 |
Why?
|
Life Style | 3 | 2021 | 3907 | 0.370 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2021 | 1624 | 0.360 |
Why?
|
Energy Intake | 2 | 2018 | 2133 | 0.360 |
Why?
|
Malaysia | 4 | 2020 | 107 | 0.350 |
Why?
|
Respiratory Tract Infections | 1 | 2018 | 1009 | 0.350 |
Why?
|
Survival Rate | 11 | 2021 | 12728 | 0.350 |
Why?
|
Tumor Microenvironment | 7 | 2023 | 3873 | 0.350 |
Why?
|
Exercise | 5 | 2021 | 5874 | 0.350 |
Why?
|
Survival Analysis | 15 | 2021 | 10088 | 0.350 |
Why?
|
Age of Onset | 6 | 2023 | 3307 | 0.340 |
Why?
|
Neoplasms | 7 | 2024 | 22140 | 0.340 |
Why?
|
Follow-Up Studies | 27 | 2024 | 39126 | 0.330 |
Why?
|
Proto-Oncogene Proteins | 6 | 2023 | 4513 | 0.330 |
Why?
|
Sirolimus | 2 | 2013 | 1540 | 0.320 |
Why?
|
Viral Load | 1 | 2018 | 3328 | 0.320 |
Why?
|
Hepacivirus | 1 | 2015 | 1330 | 0.310 |
Why?
|
Hypoglycemic Agents | 3 | 2023 | 3089 | 0.300 |
Why?
|
Colonic Polyps | 3 | 2021 | 552 | 0.300 |
Why?
|
Aged, 80 and over | 29 | 2023 | 58952 | 0.300 |
Why?
|
Drug Resistance, Neoplasm | 6 | 2020 | 5300 | 0.290 |
Why?
|
HIV-1 | 2 | 2015 | 6851 | 0.290 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 7 | 2024 | 1746 | 0.280 |
Why?
|
Mutation | 17 | 2024 | 30002 | 0.280 |
Why?
|
Cardiovascular Diseases | 3 | 2021 | 15520 | 0.280 |
Why?
|
Genetic Predisposition to Disease | 13 | 2021 | 17897 | 0.280 |
Why?
|
Incidence | 19 | 2024 | 21365 | 0.270 |
Why?
|
Neoplasm Metastasis | 6 | 2020 | 4909 | 0.270 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2018 | 3245 | 0.270 |
Why?
|
Homosexuality, Male | 1 | 2014 | 1336 | 0.260 |
Why?
|
Receptors, Calcium-Sensing | 2 | 2017 | 318 | 0.260 |
Why?
|
Phosphatidylinositol 3-Kinases | 4 | 2022 | 2864 | 0.260 |
Why?
|
Cyclooxygenase 2 | 4 | 2019 | 597 | 0.260 |
Why?
|
Prognosis | 18 | 2021 | 29687 | 0.250 |
Why?
|
Hepatitis C | 1 | 2015 | 1579 | 0.250 |
Why?
|
Sigmoidoscopy | 2 | 2022 | 151 | 0.250 |
Why?
|
Body Mass Index | 11 | 2023 | 12952 | 0.240 |
Why?
|
Double-Blind Method | 9 | 2020 | 12341 | 0.240 |
Why?
|
Precancerous Conditions | 2 | 2021 | 982 | 0.230 |
Why?
|
Leucovorin | 5 | 2022 | 643 | 0.230 |
Why?
|
Polymorphism, Single Nucleotide | 11 | 2023 | 15920 | 0.220 |
Why?
|
Genotype | 7 | 2021 | 12985 | 0.220 |
Why?
|
Adenomatous Polyps | 2 | 2021 | 109 | 0.220 |
Why?
|
United States | 26 | 2024 | 72339 | 0.220 |
Why?
|
Fusobacterium nucleatum | 2 | 2024 | 176 | 0.220 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2023 | 12159 | 0.210 |
Why?
|
DNA Mismatch Repair | 3 | 2023 | 428 | 0.210 |
Why?
|
Bacteroides fragilis | 1 | 2024 | 250 | 0.210 |
Why?
|
Cohort Studies | 21 | 2023 | 41496 | 0.210 |
Why?
|
Apolipoprotein E4 | 1 | 2007 | 709 | 0.200 |
Why?
|
Leptin | 2 | 2023 | 1595 | 0.200 |
Why?
|
Multivariate Analysis | 11 | 2020 | 12052 | 0.200 |
Why?
|
Antineoplastic Agents | 8 | 2024 | 13632 | 0.200 |
Why?
|
Body Composition | 2 | 2023 | 2427 | 0.200 |
Why?
|
Receptors, Calcitriol | 3 | 2016 | 360 | 0.190 |
Why?
|
Trifluridine | 1 | 2021 | 28 | 0.190 |
Why?
|
Peritoneal Neoplasms | 2 | 2023 | 710 | 0.190 |
Why?
|
Kaplan-Meier Estimate | 9 | 2017 | 6486 | 0.190 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2023 | 246 | 0.190 |
Why?
|
Appendiceal Neoplasms | 1 | 2023 | 155 | 0.190 |
Why?
|
Monosaccharides | 1 | 2021 | 65 | 0.180 |
Why?
|
Risk Assessment | 14 | 2024 | 24021 | 0.180 |
Why?
|
Phylogeny | 3 | 2018 | 2809 | 0.180 |
Why?
|
Gastrointestinal Neoplasms | 2 | 2023 | 955 | 0.180 |
Why?
|
Fusobacterium Infections | 1 | 2021 | 53 | 0.180 |
Why?
|
Weight Loss | 2 | 2024 | 2680 | 0.180 |
Why?
|
CA-19-9 Antigen | 1 | 2020 | 106 | 0.180 |
Why?
|
Treatment Outcome | 16 | 2024 | 64681 | 0.180 |
Why?
|
Proto-Oncogene Proteins B-raf | 6 | 2023 | 2054 | 0.170 |
Why?
|
Anus Neoplasms | 1 | 2024 | 330 | 0.170 |
Why?
|
Receptors, Leptin | 2 | 2023 | 350 | 0.170 |
Why?
|
Chromosomes, Human, Pair 2 | 1 | 2021 | 313 | 0.170 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2021 | 212 | 0.170 |
Why?
|
Flavonoids | 1 | 2023 | 444 | 0.170 |
Why?
|
Immunohistochemistry | 8 | 2024 | 11067 | 0.170 |
Why?
|
Deoxycytidine | 3 | 2023 | 878 | 0.170 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 3 | 2021 | 1089 | 0.170 |
Why?
|
Helicobacter pylori | 1 | 2023 | 382 | 0.170 |
Why?
|
Helicobacter Infections | 1 | 2023 | 392 | 0.170 |
Why?
|
Esophageal Neoplasms | 2 | 2020 | 1658 | 0.160 |
Why?
|
Asparaginase | 1 | 2020 | 239 | 0.160 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2022 | 2058 | 0.160 |
Why?
|
Odds Ratio | 7 | 2017 | 9652 | 0.150 |
Why?
|
Case-Control Studies | 11 | 2023 | 22174 | 0.150 |
Why?
|
HIV Infections | 2 | 2015 | 17347 | 0.150 |
Why?
|
Neoadjuvant Therapy | 2 | 2022 | 2827 | 0.150 |
Why?
|
Obesity | 6 | 2023 | 12939 | 0.150 |
Why?
|
Neutropenia | 1 | 2023 | 885 | 0.150 |
Why?
|
Fusobacterium | 1 | 2017 | 53 | 0.150 |
Why?
|
Receptor, IGF Type 1 | 1 | 2020 | 380 | 0.150 |
Why?
|
Sequence Analysis | 1 | 2018 | 240 | 0.150 |
Why?
|
C-Peptide | 3 | 2015 | 442 | 0.150 |
Why?
|
DNA Copy Number Variations | 2 | 2024 | 2024 | 0.140 |
Why?
|
CpG Islands | 3 | 2011 | 1190 | 0.140 |
Why?
|
Mass Screening | 4 | 2022 | 5426 | 0.140 |
Why?
|
Risk | 4 | 2020 | 9616 | 0.140 |
Why?
|
Jews | 1 | 2019 | 356 | 0.140 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2020 | 422 | 0.140 |
Why?
|
Beverages | 2 | 2022 | 821 | 0.140 |
Why?
|
Advisory Committees | 1 | 2021 | 788 | 0.140 |
Why?
|
Gene Expression Regulation, Neoplastic | 9 | 2021 | 8530 | 0.140 |
Why?
|
DNA Mutational Analysis | 4 | 2018 | 4107 | 0.140 |
Why?
|
Esophagogastric Junction | 1 | 2019 | 347 | 0.140 |
Why?
|
Protein Kinase Inhibitors | 3 | 2023 | 5662 | 0.130 |
Why?
|
Recovery of Function | 1 | 2007 | 2981 | 0.130 |
Why?
|
Coronavirus NL63, Human | 1 | 2016 | 4 | 0.130 |
Why?
|
Dietary Sucrose | 1 | 2018 | 243 | 0.130 |
Why?
|
Metronidazole | 1 | 2017 | 232 | 0.130 |
Why?
|
Coronavirus 229E, Human | 1 | 2016 | 16 | 0.130 |
Why?
|
Preventive Health Services | 1 | 2021 | 567 | 0.130 |
Why?
|
Organoplatinum Compounds | 2 | 2019 | 407 | 0.130 |
Why?
|
Tricarboxylic Acids | 1 | 2016 | 26 | 0.130 |
Why?
|
Iron Regulatory Protein 1 | 1 | 2016 | 37 | 0.130 |
Why?
|
Cause of Death | 3 | 2021 | 3688 | 0.130 |
Why?
|
Caffeine | 1 | 2020 | 701 | 0.130 |
Why?
|
Maximum Tolerated Dose | 1 | 2018 | 883 | 0.130 |
Why?
|
Sweetening Agents | 1 | 2018 | 290 | 0.130 |
Why?
|
Quantitative Trait Loci | 2 | 2021 | 2113 | 0.130 |
Why?
|
C-Reactive Protein | 3 | 2023 | 3821 | 0.130 |
Why?
|
Nuts | 1 | 2018 | 264 | 0.130 |
Why?
|
Common Cold | 1 | 2016 | 63 | 0.130 |
Why?
|
Apoptosis | 2 | 2023 | 9477 | 0.130 |
Why?
|
Smoking | 5 | 2021 | 9055 | 0.130 |
Why?
|
Combined Modality Therapy | 4 | 2020 | 8519 | 0.130 |
Why?
|
Inflammation Mediators | 2 | 2015 | 1885 | 0.130 |
Why?
|
Albumins | 1 | 2018 | 575 | 0.130 |
Why?
|
Cholangiocarcinoma | 1 | 2021 | 554 | 0.130 |
Why?
|
Postprandial Period | 1 | 2017 | 314 | 0.130 |
Why?
|
Bile Duct Neoplasms | 1 | 2021 | 607 | 0.130 |
Why?
|
Nasopharynx | 1 | 2018 | 400 | 0.120 |
Why?
|
Phenylurea Compounds | 2 | 2021 | 529 | 0.120 |
Why?
|
Medical History Taking | 1 | 2019 | 773 | 0.120 |
Why?
|
Paclitaxel | 2 | 2023 | 1730 | 0.120 |
Why?
|
Brain Injuries | 1 | 2007 | 2054 | 0.120 |
Why?
|
Neoplasms, Experimental | 1 | 2020 | 1225 | 0.120 |
Why?
|
Causality | 1 | 2021 | 1244 | 0.120 |
Why?
|
Adiponectin | 2 | 2023 | 1107 | 0.120 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2020 | 10756 | 0.120 |
Why?
|
Calcium Signaling | 1 | 2019 | 731 | 0.120 |
Why?
|
Endometrial Neoplasms | 1 | 2023 | 1366 | 0.120 |
Why?
|
Triazoles | 1 | 2020 | 902 | 0.120 |
Why?
|
Tissue Distribution | 1 | 2018 | 2263 | 0.120 |
Why?
|
Nutrition Policy | 1 | 2018 | 466 | 0.110 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 3 | 2013 | 899 | 0.110 |
Why?
|
Sex Factors | 5 | 2024 | 10553 | 0.110 |
Why?
|
Young Adult | 11 | 2023 | 59221 | 0.110 |
Why?
|
Genetic Testing | 2 | 2023 | 3537 | 0.110 |
Why?
|
Up-Regulation | 3 | 2019 | 4111 | 0.110 |
Why?
|
Leukocytes | 2 | 2019 | 2025 | 0.110 |
Why?
|
Hydrochlorothiazide | 1 | 2014 | 94 | 0.110 |
Why?
|
Kv1.1 Potassium Channel | 1 | 2013 | 30 | 0.110 |
Why?
|
Pyrimidines | 2 | 2018 | 3027 | 0.110 |
Why?
|
Diabetes Complications | 1 | 2020 | 1316 | 0.110 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2021 | 3634 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2019 | 10218 | 0.110 |
Why?
|
Growth Differentiation Factor 15 | 1 | 2015 | 197 | 0.110 |
Why?
|
Exercise Therapy | 1 | 2020 | 922 | 0.110 |
Why?
|
Parathyroid Hormone | 1 | 2020 | 1803 | 0.110 |
Why?
|
Lost to Follow-Up | 1 | 2013 | 123 | 0.110 |
Why?
|
Genetic Variation | 2 | 2018 | 6567 | 0.110 |
Why?
|
Kallikreins | 1 | 2014 | 220 | 0.110 |
Why?
|
Seasons | 2 | 2021 | 1518 | 0.100 |
Why?
|
T-Lymphocyte Subsets | 1 | 2021 | 1803 | 0.100 |
Why?
|
Cognition Disorders | 1 | 2007 | 3976 | 0.100 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2022 | 1892 | 0.100 |
Why?
|
Intention to Treat Analysis | 1 | 2013 | 413 | 0.100 |
Why?
|
Metformin | 1 | 2020 | 910 | 0.100 |
Why?
|
Asia | 1 | 2014 | 622 | 0.100 |
Why?
|
Benzamides | 1 | 2018 | 1371 | 0.100 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2021 | 1605 | 0.100 |
Why?
|
Cell Line, Tumor | 7 | 2023 | 16952 | 0.100 |
Why?
|
Age Factors | 6 | 2021 | 18384 | 0.100 |
Why?
|
Adolescent Behavior | 1 | 2021 | 1188 | 0.100 |
Why?
|
Time Factors | 11 | 2021 | 39957 | 0.100 |
Why?
|
Signal Transduction | 3 | 2020 | 23416 | 0.100 |
Why?
|
Papillomavirus Infections | 1 | 2024 | 1616 | 0.100 |
Why?
|
Genome-Wide Association Study | 6 | 2021 | 12676 | 0.100 |
Why?
|
Inflammation | 4 | 2021 | 10759 | 0.100 |
Why?
|
Nurses | 5 | 2021 | 2477 | 0.100 |
Why?
|
Adipose Tissue | 2 | 2023 | 3313 | 0.100 |
Why?
|
beta Karyopherins | 1 | 2011 | 46 | 0.090 |
Why?
|
Telomerase | 1 | 2016 | 741 | 0.090 |
Why?
|
Patient Dropouts | 1 | 2013 | 411 | 0.090 |
Why?
|
Gene Amplification | 2 | 2024 | 1084 | 0.090 |
Why?
|
Recurrence | 2 | 2021 | 8457 | 0.090 |
Why?
|
Lymph Node Excision | 1 | 2017 | 1270 | 0.090 |
Why?
|
Cluster Analysis | 1 | 2018 | 2706 | 0.090 |
Why?
|
Motor Activity | 2 | 2013 | 2712 | 0.090 |
Why?
|
Epigenesis, Genetic | 1 | 2024 | 3788 | 0.090 |
Why?
|
Hypercalcemia | 1 | 2014 | 423 | 0.090 |
Why?
|
Diabetes Mellitus | 3 | 2020 | 5842 | 0.090 |
Why?
|
Health Surveys | 2 | 2017 | 4037 | 0.090 |
Why?
|
Databases, Factual | 3 | 2021 | 7966 | 0.090 |
Why?
|
Adenoma | 1 | 2021 | 2159 | 0.090 |
Why?
|
beta Catenin | 2 | 2013 | 1042 | 0.090 |
Why?
|
Sleep Disorders, Circadian Rhythm | 1 | 2012 | 196 | 0.090 |
Why?
|
Receptors, Prostaglandin E | 1 | 2010 | 56 | 0.090 |
Why?
|
Hydroxychloroquine | 1 | 2014 | 426 | 0.090 |
Why?
|
Sequence Analysis, DNA | 1 | 2021 | 4739 | 0.080 |
Why?
|
Puerto Rico | 1 | 2011 | 378 | 0.080 |
Why?
|
RNA, Viral | 1 | 2018 | 2839 | 0.080 |
Why?
|
Germ-Line Mutation | 4 | 2020 | 1852 | 0.080 |
Why?
|
Adolescent | 10 | 2021 | 88298 | 0.080 |
Why?
|
Cell Cycle | 1 | 2017 | 2925 | 0.080 |
Why?
|
Influenza, Human | 1 | 2020 | 1521 | 0.080 |
Why?
|
Weight Gain | 1 | 2019 | 2349 | 0.080 |
Why?
|
Muscle, Skeletal | 2 | 2023 | 4947 | 0.080 |
Why?
|
DNA Methylation | 5 | 2019 | 4384 | 0.080 |
Why?
|
Somatomedins | 1 | 2008 | 179 | 0.080 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2024 | 4021 | 0.080 |
Why?
|
Gene Expression Profiling | 3 | 2019 | 9416 | 0.080 |
Why?
|
Patient Compliance | 1 | 2018 | 2688 | 0.070 |
Why?
|
Tubulin | 1 | 2011 | 692 | 0.070 |
Why?
|
Pancreatitis, Chronic | 2 | 2020 | 280 | 0.070 |
Why?
|
Acute Disease | 1 | 2018 | 7226 | 0.070 |
Why?
|
Quinolines | 1 | 2013 | 764 | 0.070 |
Why?
|
Colitis, Ulcerative | 2 | 2020 | 1920 | 0.070 |
Why?
|
Antibodies, Monoclonal | 4 | 2009 | 9187 | 0.070 |
Why?
|
Cell Differentiation | 1 | 2024 | 11509 | 0.070 |
Why?
|
Models, Genetic | 1 | 2017 | 3430 | 0.070 |
Why?
|
T-Lymphocytes | 3 | 2021 | 10203 | 0.070 |
Why?
|
Crohn Disease | 2 | 2020 | 2278 | 0.070 |
Why?
|
Fallopian Tube Neoplasms | 1 | 2009 | 328 | 0.070 |
Why?
|
MutS Homolog 2 Protein | 2 | 2017 | 197 | 0.070 |
Why?
|
Genomics | 2 | 2023 | 5828 | 0.070 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2010 | 646 | 0.070 |
Why?
|
Infant | 3 | 2023 | 36169 | 0.070 |
Why?
|
Autophagy | 1 | 2014 | 1327 | 0.070 |
Why?
|
Single-Cell Analysis | 3 | 2023 | 2451 | 0.060 |
Why?
|
Lymph Nodes | 1 | 2017 | 3461 | 0.060 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2020 | 3592 | 0.060 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2020 | 2421 | 0.060 |
Why?
|
Canada | 1 | 2011 | 2125 | 0.060 |
Why?
|
Models, Statistical | 1 | 2020 | 5081 | 0.060 |
Why?
|
Gene Frequency | 2 | 2015 | 3603 | 0.060 |
Why?
|
Chronic Disease | 2 | 2020 | 9319 | 0.060 |
Why?
|
Geriatric Assessment | 1 | 2013 | 1409 | 0.060 |
Why?
|
Glasgow Coma Scale | 1 | 2007 | 580 | 0.060 |
Why?
|
Logistic Models | 4 | 2017 | 13249 | 0.060 |
Why?
|
Genetic Loci | 1 | 2014 | 2623 | 0.060 |
Why?
|
Prostate-Specific Antigen | 1 | 2014 | 2465 | 0.060 |
Why?
|
Colonoscopy | 2 | 2022 | 1395 | 0.060 |
Why?
|
Thinking | 1 | 2007 | 319 | 0.060 |
Why?
|
Boston | 2 | 2013 | 9327 | 0.050 |
Why?
|
Taxoids | 1 | 2007 | 668 | 0.050 |
Why?
|
Receptors, Adiponectin | 1 | 2023 | 81 | 0.050 |
Why?
|
Data Collection | 1 | 2013 | 3320 | 0.050 |
Why?
|
Disease Progression | 4 | 2019 | 13511 | 0.050 |
Why?
|
Indoles | 1 | 2011 | 1830 | 0.050 |
Why?
|
Pancreatectomy | 2 | 2018 | 811 | 0.050 |
Why?
|
Animals | 9 | 2024 | 168079 | 0.050 |
Why?
|
Gene Dosage | 1 | 2007 | 1217 | 0.050 |
Why?
|
Blood Glucose | 1 | 2017 | 6392 | 0.050 |
Why?
|
Predictive Value of Tests | 6 | 2017 | 15308 | 0.050 |
Why?
|
Thymine | 1 | 2021 | 68 | 0.050 |
Why?
|
Cachexia | 1 | 2023 | 202 | 0.050 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2015 | 3803 | 0.050 |
Why?
|
Cyclin T | 1 | 2021 | 19 | 0.050 |
Why?
|
Skin Neoplasms | 1 | 2021 | 5809 | 0.050 |
Why?
|
Adipokines | 1 | 2023 | 307 | 0.050 |
Why?
|
Tea | 1 | 2023 | 288 | 0.050 |
Why?
|
Folic Acid | 1 | 2008 | 1323 | 0.050 |
Why?
|
Child | 5 | 2021 | 80152 | 0.050 |
Why?
|
Mice | 7 | 2024 | 81326 | 0.050 |
Why?
|
Ovarian Neoplasms | 2 | 2009 | 4872 | 0.050 |
Why?
|
Quinazolines | 1 | 2007 | 1371 | 0.050 |
Why?
|
MicroRNAs | 1 | 2017 | 3758 | 0.050 |
Why?
|
Retrospective Studies | 8 | 2024 | 80674 | 0.050 |
Why?
|
Intention | 1 | 2024 | 347 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 7400 | 0.050 |
Why?
|
Cell Compartmentation | 1 | 2021 | 383 | 0.050 |
Why?
|
Alu Elements | 1 | 2021 | 115 | 0.040 |
Why?
|
Seizures | 1 | 2013 | 2965 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2023 | 629 | 0.040 |
Why?
|
Muscular Atrophy | 1 | 2023 | 334 | 0.040 |
Why?
|
Lymphatic Metastasis | 2 | 2019 | 2913 | 0.040 |
Why?
|
Severity of Illness Index | 1 | 2018 | 15841 | 0.040 |
Why?
|
Fructose | 1 | 2022 | 285 | 0.040 |
Why?
|
Nutritional Requirements | 1 | 2021 | 274 | 0.040 |
Why?
|
Limit of Detection | 1 | 2021 | 273 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2016 | 8003 | 0.040 |
Why?
|
Medical Oncology | 2 | 2023 | 2320 | 0.040 |
Why?
|
HLA-DR Antigens | 1 | 2021 | 606 | 0.040 |
Why?
|
Memory Disorders | 1 | 2007 | 1198 | 0.040 |
Why?
|
Pyrrolidines | 1 | 2021 | 339 | 0.040 |
Why?
|
Disability Evaluation | 1 | 2007 | 1834 | 0.040 |
Why?
|
Molecular Targeted Therapy | 2 | 2021 | 2813 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 2 | 2019 | 20588 | 0.040 |
Why?
|
Drug Administration Schedule | 3 | 2017 | 4851 | 0.040 |
Why?
|
Anti-Bacterial Agents | 1 | 2017 | 7407 | 0.040 |
Why?
|
Rectus Abdominis | 1 | 2019 | 103 | 0.040 |
Why?
|
Cholangitis, Sclerosing | 1 | 2020 | 176 | 0.040 |
Why?
|
Protein Isoforms | 1 | 2023 | 1695 | 0.040 |
Why?
|
Coronavirus Infections | 1 | 2016 | 3093 | 0.040 |
Why?
|
Breast Neoplasms | 3 | 2020 | 20982 | 0.040 |
Why?
|
Child, Preschool | 4 | 2021 | 42224 | 0.040 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2023 | 610 | 0.040 |
Why?
|
DNA, Neoplasm | 1 | 2023 | 1743 | 0.040 |
Why?
|
Prevotella | 1 | 2017 | 80 | 0.040 |
Why?
|
Epigenomics | 1 | 2023 | 944 | 0.040 |
Why?
|
Feces | 1 | 2024 | 1490 | 0.040 |
Why?
|
HT29 Cells | 1 | 2017 | 192 | 0.040 |
Why?
|
Antigens, Bacterial | 1 | 2023 | 1140 | 0.040 |
Why?
|
Prevalence | 2 | 2013 | 15721 | 0.040 |
Why?
|
Blood Pressure | 1 | 2013 | 8479 | 0.040 |
Why?
|
Bacteroides | 1 | 2017 | 165 | 0.040 |
Why?
|
Benchmarking | 1 | 2023 | 1045 | 0.040 |
Why?
|
Chemokines | 1 | 2021 | 956 | 0.040 |
Why?
|
Memory | 1 | 2007 | 2190 | 0.040 |
Why?
|
Health Personnel | 2 | 2024 | 3337 | 0.030 |
Why?
|
Pancreatic Cyst | 1 | 2020 | 367 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2021 | 2468 | 0.030 |
Why?
|
Myeloid Cells | 1 | 2021 | 822 | 0.030 |
Why?
|
Genes, p16 | 1 | 2017 | 160 | 0.030 |
Why?
|
Diet Records | 1 | 2018 | 427 | 0.030 |
Why?
|
Aconitic Acid | 1 | 2016 | 13 | 0.030 |
Why?
|
Attention | 1 | 2007 | 2394 | 0.030 |
Why?
|
Cotinine | 1 | 2017 | 206 | 0.030 |
Why?
|
Isocitrates | 1 | 2016 | 23 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2023 | 1838 | 0.030 |
Why?
|
Bone Morphogenetic Proteins | 1 | 2021 | 840 | 0.030 |
Why?
|
Adenomatous Polyposis Coli Protein | 1 | 2017 | 181 | 0.030 |
Why?
|
DNA Glycosylases | 1 | 2017 | 124 | 0.030 |
Why?
|
Stromal Cells | 1 | 2021 | 1329 | 0.030 |
Why?
|
Long Interspersed Nucleotide Elements | 1 | 2017 | 330 | 0.030 |
Why?
|
Immunity | 1 | 2021 | 996 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2019 | 858 | 0.030 |
Why?
|
Penetrance | 1 | 2017 | 382 | 0.030 |
Why?
|
Nutritive Value | 1 | 2018 | 347 | 0.030 |
Why?
|
Tumor Necrosis Factors | 1 | 2015 | 109 | 0.030 |
Why?
|
3' Untranslated Regions | 1 | 2017 | 514 | 0.030 |
Why?
|
Polymerase Chain Reaction | 2 | 2014 | 6067 | 0.030 |
Why?
|
Mice, Inbred Strains | 1 | 2017 | 1762 | 0.030 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2023 | 2426 | 0.030 |
Why?
|
Administration, Oral | 2 | 2013 | 4015 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2021 | 14610 | 0.030 |
Why?
|
Flurothyl | 1 | 2013 | 10 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1791 | 0.030 |
Why?
|
Kindling, Neurologic | 1 | 2013 | 24 | 0.030 |
Why?
|
Comorbidity | 2 | 2022 | 10516 | 0.030 |
Why?
|
Pancreaticoduodenectomy | 1 | 2017 | 509 | 0.030 |
Why?
|
Neuropsychological Tests | 1 | 2007 | 7046 | 0.030 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2016 | 413 | 0.030 |
Why?
|
Gene Expression Regulation, Viral | 1 | 2016 | 433 | 0.030 |
Why?
|
Genes, BRCA2 | 1 | 2017 | 591 | 0.030 |
Why?
|
Databases, Genetic | 1 | 2020 | 1741 | 0.030 |
Why?
|
Recombinant Proteins | 1 | 2023 | 6504 | 0.030 |
Why?
|
Antihypertensive Agents | 1 | 2023 | 2019 | 0.030 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2017 | 2915 | 0.030 |
Why?
|
Telomere | 1 | 2019 | 939 | 0.030 |
Why?
|
Genes, BRCA1 | 1 | 2017 | 754 | 0.030 |
Why?
|
Body Weight | 1 | 2024 | 4618 | 0.030 |
Why?
|
Microsatellite Repeats | 1 | 2015 | 782 | 0.030 |
Why?
|
Hypertension | 1 | 2013 | 8536 | 0.030 |
Why?
|
Databases as Topic | 1 | 2015 | 473 | 0.030 |
Why?
|
Karnofsky Performance Status | 1 | 2013 | 166 | 0.030 |
Why?
|
Regression Analysis | 2 | 2015 | 6345 | 0.030 |
Why?
|
Discriminant Analysis | 1 | 2012 | 224 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2017 | 1008 | 0.030 |
Why?
|
Celiac Disease | 1 | 2020 | 819 | 0.020 |
Why?
|
Escherichia coli | 1 | 2024 | 4201 | 0.020 |
Why?
|
Monocytes | 1 | 2021 | 2570 | 0.020 |
Why?
|
MAP Kinase Signaling System | 1 | 2018 | 1480 | 0.020 |
Why?
|
Diuretics | 1 | 2014 | 611 | 0.020 |
Why?
|
Colon | 1 | 2019 | 1791 | 0.020 |
Why?
|
Cell Count | 1 | 2015 | 1831 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2023 | 22127 | 0.020 |
Why?
|
Infant, Newborn | 2 | 2021 | 26199 | 0.020 |
Why?
|
Population Surveillance | 1 | 2021 | 2598 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2018 | 2011 | 0.020 |
Why?
|
Mice, Mutant Strains | 1 | 2013 | 1751 | 0.020 |
Why?
|
Receptors, Prostaglandin E, EP2 Subtype | 1 | 2010 | 48 | 0.020 |
Why?
|
DNA | 1 | 2024 | 7189 | 0.020 |
Why?
|
Propensity Score | 1 | 2017 | 1916 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2020 | 5250 | 0.020 |
Why?
|
Bacterial Proteins | 1 | 2023 | 3836 | 0.020 |
Why?
|
DNA-Binding Proteins | 2 | 2017 | 9566 | 0.020 |
Why?
|
Pyridines | 1 | 2021 | 2872 | 0.020 |
Why?
|
Proteomics | 1 | 2023 | 3840 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2018 | 1743 | 0.020 |
Why?
|
Placebos | 1 | 2013 | 1666 | 0.020 |
Why?
|
ROC Curve | 1 | 2017 | 3584 | 0.020 |
Why?
|
DNA Repair | 1 | 2018 | 2041 | 0.020 |
Why?
|
Microtubule-Associated Proteins | 1 | 2014 | 1075 | 0.020 |
Why?
|
Viral Proteins | 1 | 2016 | 1798 | 0.020 |
Why?
|
Receptor, erbB-3 | 1 | 2009 | 142 | 0.020 |
Why?
|
Neutrophils | 1 | 2021 | 3763 | 0.020 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2009 | 318 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2021 | 3551 | 0.020 |
Why?
|
Work Schedule Tolerance | 1 | 2012 | 553 | 0.020 |
Why?
|
Insulin-Like Growth Factor Binding Protein 1 | 1 | 2008 | 126 | 0.020 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2020 | 2517 | 0.020 |
Why?
|
Animals, Newborn | 1 | 2013 | 2665 | 0.020 |
Why?
|
Gene Expression | 1 | 2020 | 7571 | 0.020 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2008 | 208 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2021 | 7571 | 0.020 |
Why?
|
Focus Groups | 1 | 2012 | 1413 | 0.020 |
Why?
|
Cell Line | 1 | 2021 | 15545 | 0.020 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 1 | 2008 | 415 | 0.020 |
Why?
|
Heterozygote | 1 | 2013 | 2778 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2017 | 2803 | 0.020 |
Why?
|
Bone Density Conservation Agents | 1 | 2014 | 793 | 0.020 |
Why?
|
Macrophages | 1 | 2021 | 5753 | 0.020 |
Why?
|
Demography | 1 | 2011 | 1641 | 0.020 |
Why?
|
Lymphocytes | 1 | 2014 | 2603 | 0.020 |
Why?
|
Insurance Coverage | 1 | 2017 | 1935 | 0.020 |
Why?
|
Women's Health | 1 | 2016 | 2070 | 0.020 |
Why?
|
Sex Characteristics | 1 | 2016 | 2640 | 0.020 |
Why?
|
Genes, erbB-2 | 1 | 2006 | 162 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2017 | 1847 | 0.020 |
Why?
|
Drug Delivery Systems | 1 | 2017 | 2223 | 0.020 |
Why?
|
Dietary Carbohydrates | 1 | 2010 | 891 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14675 | 0.020 |
Why?
|
Alleles | 1 | 2016 | 6857 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2020 | 12976 | 0.020 |
Why?
|
Nanoparticles | 1 | 2017 | 1959 | 0.020 |
Why?
|
Insurance, Health | 1 | 2017 | 2493 | 0.020 |
Why?
|
Alcohol Drinking | 1 | 2018 | 4027 | 0.020 |
Why?
|
Orchiectomy | 1 | 2007 | 463 | 0.010 |
Why?
|
Dimerization | 1 | 2006 | 887 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2007 | 11101 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2021 | 7851 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2014 | 6304 | 0.010 |
Why?
|
Single-Blind Method | 1 | 2007 | 1577 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 4567 | 0.010 |
Why?
|
Phenotype | 2 | 2011 | 16575 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 2017 | 5782 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2008 | 3418 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2017 | 3354 | 0.010 |
Why?
|
Liver Neoplasms | 1 | 2017 | 4309 | 0.010 |
Why?
|
Probability | 1 | 2007 | 2478 | 0.010 |
Why?
|
Registries | 1 | 2017 | 8247 | 0.010 |
Why?
|
Circadian Rhythm | 1 | 2012 | 2569 | 0.010 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2008 | 1933 | 0.010 |
Why?
|
Calcium | 1 | 2014 | 5719 | 0.010 |
Why?
|
Hippocampus | 1 | 2013 | 3754 | 0.010 |
Why?
|
Massachusetts | 1 | 2013 | 8837 | 0.010 |
Why?
|
Hospitalization | 1 | 2020 | 10707 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2017 | 20119 | 0.010 |
Why?
|
Decision Making | 1 | 2013 | 3931 | 0.010 |
Why?
|
Pregnancy | 1 | 2020 | 29893 | 0.010 |
Why?
|
Electroencephalography | 1 | 2013 | 6242 | 0.010 |
Why?
|
Algorithms | 1 | 2017 | 14025 | 0.010 |
Why?
|
Transcription Factors | 1 | 2016 | 12099 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2009 | 12747 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2013 | 18220 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2011 | 26071 | 0.010 |
Why?
|